FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387157098> ?p ?o ?g. }

• W4387157098 abstract "To investigate the clinicopathological characteristics and prognostic factors of early-stage breast cancer (EBC) with human epidermal growth factor receptor 2 (HER2)-low expression.The clinicopathological data and follow-up information of EBC patients with HER2-low and HER2-0 expression treated at the Breast Disease Center of Peking University First Hospital from January 2014 to December 2017 were analyzed. The prognosis between HER2-low and HER2-0 expression groups and with different hormone receptor (HR) expression were compared by statistics. Meanwhile, the expression of Ki67, androgen receptor (AR), TOPIIa, P53, PTEN, and CK5/6 were also analyzed with the HER2-low expression and prognosis.Retrospectively analyzed 1253 cases of EBC, including 583 (46.5%) cases of HER2-low breast cancer (BC) and 366 (29.2%) HER2-0 BC cases. Among the HER2-low BC patients, 487 (83.5%) were HR-positive, while 96 (16.5%) were HR-negative. Among the HER2-0 BC patients, 265 (72.4%) were HR-positive, while 101 (27.6%) were HR-negative. Median follow-up time was 53 months. The 5-year disease-free survival of HER2-low BC patients was 90.2% (95% confidence interval [CI]: 87.2-93.1), and the 5-year overall survival was 95.4% (95% CI: 93.3-97.6). Cox regression analysis showed that T stage, lymphovascular invasion, and/or perineural invasion were prognostic factors of HER2-low BC patients. However, the 5-year disease-free survival and overall survival of patients in the HER2-low and HER2-0 groups were not significantly different in all patients, but a tendency of better prognosis in HER2-low group was seen in HR-negative tumors.HER2-low EBC patients accounted for 46.5% of the patient population. T stage, lymphovascular invasion, and/or perineural invasion were factors affecting the prognosis of BC patients with low HER2 expression. No significant difference in prognosis was noted between HER2-low and HER2-0 EBC patients. But in HR-negative tumors, a tendency of better prognosis was seen in HER2-low versus HER2-0." @default.
• W4387157098 created "2023-09-30" @default.
• W4387157098 creator A5002744113 @default.
• W4387157098 creator A5026242206 @default.
• W4387157098 creator A5032019840 @default.
• W4387157098 creator A5049289892 @default.
• W4387157098 creator A5069849278 @default.
• W4387157098 creator A5074368591 @default.
• W4387157098 creator A5077581333 @default.
• W4387157098 date "2023-09-29" @default.
• W4387157098 modified "2023-09-30" @default.
• W4387157098 title "Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer" @default.
• W4387157098 cites W1813571362 @default.
• W4387157098 cites W2037528210 @default.
• W4387157098 cites W2099335989 @default.
• W4387157098 cites W2101979288 @default.
• W4387157098 cites W2117775530 @default.
• W4387157098 cites W2120431466 @default.
• W4387157098 cites W2137355132 @default.
• W4387157098 cites W2137853125 @default.
• W4387157098 cites W2150134401 @default.
• W4387157098 cites W2314772071 @default.
• W4387157098 cites W2502134830 @default.
• W4387157098 cites W2802207314 @default.
• W4387157098 cites W2807966236 @default.
• W4387157098 cites W2943977338 @default.
• W4387157098 cites W2995712298 @default.
• W4387157098 cites W3005585857 @default.
• W4387157098 cites W3018222852 @default.
• W4387157098 cites W3119128530 @default.
• W4387157098 cites W3128646645 @default.
• W4387157098 cites W3143953357 @default.
• W4387157098 cites W3149713943 @default.
• W4387157098 cites W3160468108 @default.
• W4387157098 cites W3179156059 @default.
• W4387157098 cites W3206797759 @default.
• W4387157098 cites W4200612810 @default.
• W4387157098 cites W4206299960 @default.
• W4387157098 cites W4206841660 @default.
• W4387157098 cites W4220923708 @default.
• W4387157098 cites W4281640394 @default.
• W4387157098 cites W4321612614 @default.
• W4387157098 cites W4323307186 @default.
• W4387157098 cites W4378978327 @default.
• W4387157098 doi "https://doi.org/10.1002/cam4.6571" @default.
• W4387157098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37772432" @default.
• W4387157098 hasPublicationYear "2023" @default.
• W4387157098 type Work @default.
• W4387157098 citedByCount "0" @default.
• W4387157098 crossrefType "journal-article" @default.
• W4387157098 hasAuthorship W4387157098A5002744113 @default.
• W4387157098 hasAuthorship W4387157098A5026242206 @default.
• W4387157098 hasAuthorship W4387157098A5032019840 @default.
• W4387157098 hasAuthorship W4387157098A5049289892 @default.
• W4387157098 hasAuthorship W4387157098A5069849278 @default.
• W4387157098 hasAuthorship W4387157098A5074368591 @default.
• W4387157098 hasAuthorship W4387157098A5077581333 @default.
• W4387157098 hasBestOaLocation W43871570981 @default.
• W4387157098 hasConcept C121608353 @default.
• W4387157098 hasConcept C126322002 @default.
• W4387157098 hasConcept C143998085 @default.
• W4387157098 hasConcept C146357865 @default.
• W4387157098 hasConcept C151730666 @default.
• W4387157098 hasConcept C23589133 @default.
• W4387157098 hasConcept C2777154038 @default.
• W4387157098 hasConcept C2778740770 @default.
• W4387157098 hasConcept C2779013556 @default.
• W4387157098 hasConcept C2908728163 @default.
• W4387157098 hasConcept C44249647 @default.
• W4387157098 hasConcept C50382708 @default.
• W4387157098 hasConcept C530470458 @default.
• W4387157098 hasConcept C71924100 @default.
• W4387157098 hasConcept C84606932 @default.
• W4387157098 hasConcept C86803240 @default.
• W4387157098 hasConcept C98717036 @default.
• W4387157098 hasConceptScore W4387157098C121608353 @default.
• W4387157098 hasConceptScore W4387157098C126322002 @default.
• W4387157098 hasConceptScore W4387157098C143998085 @default.
• W4387157098 hasConceptScore W4387157098C146357865 @default.
• W4387157098 hasConceptScore W4387157098C151730666 @default.
• W4387157098 hasConceptScore W4387157098C23589133 @default.
• W4387157098 hasConceptScore W4387157098C2777154038 @default.
• W4387157098 hasConceptScore W4387157098C2778740770 @default.
• W4387157098 hasConceptScore W4387157098C2779013556 @default.
• W4387157098 hasConceptScore W4387157098C2908728163 @default.
• W4387157098 hasConceptScore W4387157098C44249647 @default.
• W4387157098 hasConceptScore W4387157098C50382708 @default.
• W4387157098 hasConceptScore W4387157098C530470458 @default.
• W4387157098 hasConceptScore W4387157098C71924100 @default.
• W4387157098 hasConceptScore W4387157098C84606932 @default.
• W4387157098 hasConceptScore W4387157098C86803240 @default.
• W4387157098 hasConceptScore W4387157098C98717036 @default.
• W4387157098 hasLocation W43871570981 @default.
• W4387157098 hasLocation W43871570982 @default.
• W4387157098 hasOpenAccess W4387157098 @default.
• W4387157098 hasPrimaryLocation W43871570981 @default.
• W4387157098 hasRelatedWork W2000536166 @default.
• W4387157098 hasRelatedWork W2120574916 @default.
• W4387157098 hasRelatedWork W2131551233 @default.
• W4387157098 hasRelatedWork W2144393269 @default.

• next